Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK announces data transparency initiative
The information can be found in the GSK Clinical Trial Register (CTR), a database accessible through the home page of the company's website. “We have created a record
The information can be found in the GSK Clinical Trial Register (CTR), a database accessible through the home page of the company's website. “We have created a record
The functioning assessment was part of a larger trial, of which the primary endpoint was to examine the ability of atomoxetine, the active ingredient in Strattera, to treat
The common cold (rhinovirus) is a major factor behind the worsening of chronic obstructive pulmonary disease (COPD) symptoms and resultant hospitalizations. Preliminary data presented by Synairgen at this
A multicenter, double-blind, placebo-controlled study followed outpatients with major depression through acute, continuation and two phases of maintenance therapy (12 months each) with venlafaxine extended release compared to
Confirming the results of an earlier study, AstraZeneca's Seroquel (quetiapine fumarate) has demonstrated significant improvement in measures of depressive symptoms in a large-scale study examining the drug as
The library, developed by Dr Leroy Townsend, consists of lead candidates specifically designed toward key antiviral and oncology targets. Chimerix will incorporate promising candidates from the antiviral library
A preclinical evaluation study investigated the tolerability and anticancer activity of the mycobacterial cell wall-DNA complex (MCC) suspension, trademarked Urocidin, after intraperitoneal administration using a rat peritoneal DHD/K12/PROb
The randomization of 820 patients with osteoarthritis (OA) of the knee at 120 clinical sites in the US was initiated in late December 2005 and has now been
Bavituximab (formerly Tarvacin) is a monoclonal antibody with unique anti-viral and anticancer properties that has already demonstrated good tolerability in a phase I trial in patients with hepatitis
Under the terms of the agreement, Roche will provide R&D funding and milestone payments, and Entelos will conduct biosimulation research using its Metabolism PhysioLab platform, which utilizes a